NYSE:VRX - Valeant Pharmaceuticals Intl Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$22.24 +0.02 (+0.09 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$22.24
Today's Range$22.09 - $22.3160
52-Week Range$10.94 - $24.43
Volume3.47 million shs
Average Volume10.77 million shs
Market Capitalization$7.75 billion
P/E Ratio5.81
Dividend YieldN/A
Beta-0.35

About Valeant Pharmaceuticals Intl (NYSE:VRX)

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:VRX
CUSIPN/A
Phone514-744-6792

Debt

Debt-to-Equity Ratio5.59
Current Ratio1.18
Quick Ratio0.92

Price-To-Earnings

Trailing P/E Ratio5.81
Forward P/E Ratio6.68
P/E Growth0.43

Sales & Book Value

Annual Sales$8.72 billion
Price / Sales0.89
Cash Flow$12.4944 per share
Price / Cash1.78
Book Value$12.95 per share
Price / Book1.72

Profitability

EPS (Most Recent Fiscal Year)$3.83
Net Income$2.40 billion
Net Margins-10.65%
Return on Equity27.87%
Return on Assets3.58%

Miscellaneous

Employees20,700
Outstanding Shares349,300,000

Valeant Pharmaceuticals Intl (NYSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals Intl's earnings last quarter?

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) released its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported $0.89 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.60 by $0.29. The specialty pharmaceutical company earned $2 billion during the quarter, compared to the consensus estimate of $1.95 billion. Valeant Pharmaceuticals Intl had a positive return on equity of 27.87% and a negative net margin of 10.65%. The company's quarterly revenue was down 5.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.79 earnings per share. View Valeant Pharmaceuticals Intl's Earnings History.

What price target have analysts set for VRX?

19 brokerages have issued 1-year price targets for Valeant Pharmaceuticals Intl's shares. Their predictions range from $9.00 to $45.00. On average, they expect Valeant Pharmaceuticals Intl's stock price to reach $19.2353 in the next year. View Analyst Ratings for Valeant Pharmaceuticals Intl.

What are Wall Street analysts saying about Valeant Pharmaceuticals Intl stock?

Here are some recent quotes from research analysts about Valeant Pharmaceuticals Intl stock:
  • 1. HC Wainwright analysts commented, "Exchange NYSE Value (M) $31,421.0 Market Cap (M) $7,064 Public Market Float (M) 329.9 Shares Outstanding (M) 348.8 3 Interest (M) 40.90 Cash (M) $909.0 Total Debt (M) $25,266.0 Year – (0.25) FY 6.86 (7.48) (1.32) FY P/E 3.0x NM NM Year – 2,290.0 FY 8,724.0 8,325.0 8,810.0 30 25 20 15 10 0 Vol." (5/7/2018)
  • 2. According to Zacks Investment Research, "Valeant’s Bausch + Lomb/International segment and Salix businesses are doing well and should propel the top-line in the coming quarters. The approval of new drugs should boost the top line. After a tumultuous period, Valeant started a rebuilding process with its CEO, Joseph C. Papa. Shares of the company have outperformed the industry in the last six months. Even though it is still early to comment on the rebuilding process but the company’s efforts to sell non-core assets and pay lower debt is commendable. As of Feb 28, 2018, the company reduced total debt by approximately $6.7 billion since the end of first-quarter 2016. The dermatology business remains challenging and is expected to decline in 2018 as compared to 2017.  The guidance for 2018 was disappointing. Hence, it might be a while before the company turn arounds as management had projected." (4/2/2018)
  • 3. Cantor Fitzgerald analysts commented, "There has been some concern that VRX’s Xifaxan could face competition from Cosmo Pharmaceuticals (Not Covered) as early as 2019. We reiterate our Overweight rating and price target of $25; we don’t see fundamental reasons for the stock’s weakness this morning." (1/19/2018)

Are investors shorting Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl saw a decline in short interest during the month of May. As of May 15th, there was short interest totalling 18,097,653 shares, a decline of 15.9% from the April 30th total of 21,514,198 shares. Based on an average daily trading volume, of 13,863,988 shares, the short-interest ratio is presently 1.3 days. Currently, 5.3% of the company's shares are sold short.

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who are Valeant Pharmaceuticals Intl's key executives?

Valeant Pharmaceuticals Intl's management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 63)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
  • Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
  • Mr. J. Michael Pearson, Former Chief Exec. Officer (Age 59)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 46)

Has Valeant Pharmaceuticals Intl been receiving favorable news coverage?

News coverage about VRX stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Valeant Pharmaceuticals Intl earned a coverage optimism score of 0.12 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 46.66 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Valeant Pharmaceuticals Intl's major shareholders?

Valeant Pharmaceuticals Intl's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (1.63%), CIBC World Markets Inc. (0.97%), Fosun International Ltd (0.50%), Chou Associates Management Inc. (0.47%), Legal & General Group Plc (0.42%) and Private Management Group Inc. (0.36%). Company insiders that own Valeant Pharmaceuticals Intl stock include Argeris N Karabelas, John Paulson, Joseph C Papa, Paul Herendeen, Pershing Square Capital Manage, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Institutional Ownership Trends for Valeant Pharmaceuticals Intl.

Which major investors are selling Valeant Pharmaceuticals Intl stock?

VRX stock was sold by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, OppenheimerFunds Inc., Schroder Investment Management Group, Hsbc Holdings PLC, Legal & General Group Plc, Vertex One Asset Management Inc., Swiss National Bank and Blair William & Co. IL. View Insider Buying and Selling for Valeant Pharmaceuticals Intl.

Which major investors are buying Valeant Pharmaceuticals Intl stock?

VRX stock was acquired by a variety of institutional investors in the last quarter, including Fosun International Ltd, Chou Associates Management Inc., O Shaughnessy Asset Management LLC, Dimensional Fund Advisors LP, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Point72 Asset Management L.P., Miracle Mile Advisors LLC and CIBC Asset Management Inc. Company insiders that have bought Valeant Pharmaceuticals Intl stock in the last two years include Argeris N Karabelas, John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Insider Buying and Selling for Valeant Pharmaceuticals Intl.

How do I buy shares of Valeant Pharmaceuticals Intl?

Shares of VRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Valeant Pharmaceuticals Intl's stock price today?

One share of VRX stock can currently be purchased for approximately $22.24.

How big of a company is Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl has a market capitalization of $7.75 billion and generates $8.72 billion in revenue each year. The specialty pharmaceutical company earns $2.40 billion in net income (profit) each year or $3.83 on an earnings per share basis. Valeant Pharmaceuticals Intl employs 20,700 workers across the globe.

How can I contact Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl's mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The specialty pharmaceutical company can be reached via phone at 514-744-6792 or via email at [email protected]


MarketBeat Community Rating for Valeant Pharmaceuticals Intl (VRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  1,231 (Vote Outperform)
Underperform Votes:  1,099 (Vote Underperform)
Total Votes:  2,330
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Valeant Pharmaceuticals Intl (NYSE:VRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Valeant Pharmaceuticals Intl in the last 12 months. Their average twelve-month price target is $19.2353, suggesting that the stock has a possible downside of 13.51%. The high price target for VRX is $45.00 and the low price target for VRX is $9.00. There are currently 4 sell ratings, 8 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.162.102.052.11
Ratings Breakdown: 4 Sell Rating(s)
8 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
10 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
9 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
11 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.2353$18.50$18.6316$17.3333
Price Target Upside: 13.51% downside17.16% upside0.28% upside19.95% upside

Valeant Pharmaceuticals Intl (NYSE:VRX) Consensus Price Target History

Price Target History for Valeant Pharmaceuticals Intl (NYSE:VRX)

Valeant Pharmaceuticals Intl (NYSE:VRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018MizuhoUpgradeNeutral ➝ BuyLowView Rating Details
5/14/2018Cantor FitzgeraldSet Price TargetBuy$25.00LowView Rating Details
5/11/2018BMO Capital MarketsBoost Price TargetMarket Perform$17.00 ➝ $20.00LowView Rating Details
5/9/2018BTIG ResearchReiterated RatingHoldLowView Rating Details
5/9/2018Jefferies GroupBoost Price TargetBuy$23.00LowView Rating Details
5/9/2018TD SecuritiesBoost Price TargetBuy$23.00 ➝ $24.00LowView Rating Details
5/9/2018Royal Bank of CanadaBoost Price TargetSector Perform$18.00 ➝ $19.00LowView Rating Details
5/9/2018JPMorgan Chase & Co.Set Price TargetSell$13.00HighView Rating Details
5/9/2018Piper Jaffray CompaniesSet Price TargetSell$13.00LowView Rating Details
5/8/2018Goldman Sachs GroupSet Price TargetSell$16.00MediumView Rating Details
5/7/2018HC WainwrightReiterated RatingPositive ➝ Hold$16.00MediumView Rating Details
4/30/2018Deutsche BankBoost Price TargetBuy$20.00 ➝ $22.00LowView Rating Details
3/20/2018Wells Fargo & CoReiterated RatingSellMediumView Rating Details
2/28/2018CfraDowngradeHoldHighView Rating Details
10/3/2017Canaccord GenuityReiterated RatingHold$16.00LowView Rating Details
8/21/2017Stifel NicolausReiterated RatingBuy$45.00MediumView Rating Details
8/10/2017Rodman & RenshawReiterated RatingNeutral$17.00HighView Rating Details
8/9/2017ScotiabankBoost Price TargetSector Perform$14.00 ➝ $16.00MediumView Rating Details
6/17/2017GuggenheimInitiated CoverageBuy$18.00HighView Rating Details
5/23/2017BarclaysReiterated RatingHold$20.00LowView Rating Details
3/11/2017Morgan StanleyReiterated RatingEqual Weight$17.00 ➝ $12.00N/AView Rating Details
5/29/2016Susquehanna BancsharesReiterated RatingHold$105.00N/AView Rating Details
5/29/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Valeant Pharmaceuticals Intl (NYSE:VRX) Earnings History and Estimates Chart

Earnings by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Valeant Pharmaceuticals Intl (NYSE:VRX) Earnings Estimates

2018 EPS Consensus Estimate: $2.41
2019 EPS Consensus Estimate: $3.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181$0.78$0.78$0.78
Q3 20182$0.70$0.92$0.81
Q4 20182$0.71$0.92$0.82
Q1 20191$0.83$0.83$0.83
Q2 20191$0.86$0.86$0.86
Q3 20191$0.90$0.90$0.90
Q4 20191$0.93$0.93$0.93

Valeant Pharmaceuticals Intl (NYSE VRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/20183/31/2018$0.60$0.89$1.9496 billion$1.9950 billionViewListenView Earnings Details
2/28/2018n/a$0.96$0.98$2.1793 billion$2.1630 billionViewN/AView Earnings Details
11/7/2017Q3 2017$0.90$1.04$2.1689 billion$2.2190 billionViewN/AView Earnings Details
8/8/20176/30/2017$0.97$1.05$2.2298 billion$2.2330 billionViewListenView Earnings Details
5/9/20173/31/2017$0.87$2.80$2.1715 billion$2.1090 billionViewListenView Earnings Details
2/28/2017Q416$1.20$1.26$2.34 billion$2.4030 billionViewListenView Earnings Details
11/8/2016Q316$1.78$1.55$2.49 billion$2.48 billionViewListenView Earnings Details
8/9/2016Q216$1.48$1.40$2.47 billion$2.42 billionViewN/AView Earnings Details
6/7/2016Q116$1.37$1.27$2.3376 billion$2.37 billionViewN/AView Earnings Details
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details
10/19/2015Q315$2.6830$2.74$2.06 billion$2.79 billionViewListenView Earnings Details
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details
2/24/2015Q414$2.56$2.58$2.2265 billion$2.28 billionViewN/AView Earnings Details
10/20/2014Q314$1.99$2.11$2.0621 billion$2.06 billionViewListenView Earnings Details
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details
8/2/2012$0.99$1.01ViewN/AView Earnings Details
5/3/2012$0.96$0.99ViewN/AView Earnings Details
2/27/2012Q4 2011$0.85$0.90ViewN/AView Earnings Details
11/3/2011$0.57$0.66ViewN/AView Earnings Details
8/4/2011$0.65$0.73ViewN/AView Earnings Details
5/9/2011$0.51$0.56ViewN/AView Earnings Details
2/24/2011$0.45$0.51ViewN/AView Earnings Details
11/4/2010Q3 2010$0.34($0.28)ViewN/AView Earnings Details
8/5/2010Q2 2010$0.26$0.35ViewN/AView Earnings Details
5/6/2010Q1 2010$0.27$0.54ViewN/AView Earnings Details
2/25/2010Q4 2009$0.40$0.56ViewN/AView Earnings Details
11/5/2009Q3 2009$0.42$0.32ViewN/AView Earnings Details
8/6/2009Q2 2009$0.34$0.34ViewN/AView Earnings Details
5/6/2009Q1 2009$0.30$0.41ViewN/AView Earnings Details
2/26/2009Q4 2008$0.30$0.34ViewN/AView Earnings Details
11/6/2008Q3 2008$0.27$0.35ViewN/AView Earnings Details
8/13/2008Q2 2008$0.34$0.37ViewN/AView Earnings Details
5/8/2008Q1 2008$0.41$0.43ViewN/AView Earnings Details
3/13/2008Q4 2007$0.39$0.45ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Valeant Pharmaceuticals Intl (NYSE:VRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Valeant Pharmaceuticals Intl (NYSE VRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.87%
Institutional Ownership Percentage: 50.13%
Insider Trading History for Valeant Pharmaceuticals Intl (NYSE:VRX)
Institutional Ownership by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Valeant Pharmaceuticals Intl (NYSE VRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018Schutter Richard U DeDirectorBuy15,000$21.83$327,450.00View SEC Filing  
3/13/2018Joseph C PapaCEOBuy30,000$16.05$481,500.00View SEC Filing  
3/13/2018Paul HerendeenCFOBuy15,000$16.10$241,500.00View SEC Filing  
3/8/2018Schutter Richard U DeDirectorBuy10,000$15.34$153,400.00106,062View SEC Filing  
3/6/2018John PaulsonDirectorBuy7,066,629$15.40$108,826,086.60View SEC Filing  
11/16/2017John PaulsonDirectorBuy344,216$14.40$4,956,710.4094,559View SEC Filing  
8/21/2017Schutter Richard U DeDirectorBuy10,000$14.33$143,300.0077,479View SEC Filing  
5/11/2017Schutter Richard U DeDirectorBuy20,000$13.90$278,000.0070,572View SEC Filing  
3/15/2017Schutter Richard U DeDirectorBuy10,000$10.80$108,000.0025,190View SEC Filing  
3/14/2017Paul HerendeenCFOBuy24,000$10.72$257,280.00174,000View SEC Filing  
3/14/2017Valueact Capital Master Fund,InsiderBuy3,000,000$10.82$32,460,000.00View SEC Filing  
3/13/2017Pershing Square Capital ManageDirectorSell18,114,432$11.00$199,258,752.00View SEC Filing  
12/14/2016Thomas W Sr. RossDirectorBuy5,000$14.73$73,650.0026,822View SEC Filing  
12/12/2016Pershing Square Capital ManageDirectorSell3,476,690$14.85$51,628,846.50View SEC Filing  
8/11/2016Argeris N KarabelasDirectorBuy4,000$24.65$98,600.0020,726View SEC Filing  
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.002,442,199View SEC Filing  
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.0015,532View SEC Filing  
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.0023,999View SEC Filing  
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00137,495View SEC Filing  
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.5753,582View SEC Filing  
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00147,206View SEC Filing  
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.4028,390View SEC Filing  
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00152,206View SEC Filing  
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.274,025,498View SEC Filing  
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.0016,500View SEC Filing  
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.0027,808View SEC Filing  
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.008,500View SEC Filing  
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00167,282View SEC Filing  
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.0053,969View SEC Filing  
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.0026,057View SEC Filing  
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60188,277View SEC Filing  
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.0032,156View SEC Filing  
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.007,500View SEC Filing  
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Valeant Pharmaceuticals Intl (NYSE VRX) News Headlines

Source:
DateHeadline
[$$] A closer look at the great Maryland pension fees debate[$$] A closer look at the great Maryland pension fees debate
finance.yahoo.com - May 23 at 8:09 AM
Cantor Fitzgerald Analysts Boost Earnings Estimates for Valeant Pharmaceuticals Intl Inc (VRX)Cantor Fitzgerald Analysts Boost Earnings Estimates for Valeant Pharmaceuticals Intl Inc (VRX)
www.americanbankingnews.com - May 23 at 7:08 AM
Former CEO of Hatboro mail-order pharmacy convicted of fraud, money laundering chargesFormer CEO of Hatboro mail-order pharmacy convicted of fraud, money laundering charges
finance.yahoo.com - May 22 at 5:16 PM
[$$] Leveraged loan rush sees borrowers gain balance of power[$$] Leveraged loan rush sees borrowers gain balance of power
finance.yahoo.com - May 22 at 8:09 AM
Valeant Pharmaceuticals: Worth At Least $30Valeant Pharmaceuticals: Worth At Least $30
seekingalpha.com - May 21 at 8:05 AM
Valeant Pharmaceuticals International Inc (VRX) Receives Consensus Rating of "Hold" from BrokeragesValeant Pharmaceuticals International Inc (VRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 20 at 3:40 AM
Insider Buying: Valeant Pharmaceuticals International Inc (VRX) Director Buys 15,000 Shares of StockInsider Buying: Valeant Pharmaceuticals International Inc (VRX) Director Buys 15,000 Shares of Stock
www.americanbankingnews.com - May 17 at 8:15 PM
Valeant launches $750 million bond offering, increases planned Term B loan borrowingValeant launches $750 million bond offering, increases planned Term B loan borrowing
finance.yahoo.com - May 17 at 8:07 AM
Valeant Pharmaceuticals’ U.S. Diversified Products in 1Q18Valeant Pharmaceuticals’ U.S. Diversified Products in 1Q18
finance.yahoo.com - May 17 at 8:07 AM
Valeant Pharmaceuticals’ Ortho Dermatology SegmentValeant Pharmaceuticals’ Ortho Dermatology Segment
finance.yahoo.com - May 16 at 5:58 PM
How Valeant’s Xifaxan and Other Branded Drugs Performed in 1Q18How Valeant’s Xifaxan and Other Branded Drugs Performed in 1Q18
finance.yahoo.com - May 16 at 5:58 PM
Mizuho Upgrades Valeant Pharmaceuticals International (VRX) to BuyMizuho Upgrades Valeant Pharmaceuticals International (VRX) to Buy
www.americanbankingnews.com - May 15 at 1:23 PM
Form 8-K Valeant Pharmaceuticals For: May 14Form 8-K Valeant Pharmaceuticals For: May 14
www.streetinsider.com - May 15 at 8:10 AM
Bill Ackmans Big Deals Dont Look Better in HindsightBill Ackman's Big Deals Don't Look Better in Hindsight
www.bloomberg.com - May 15 at 8:10 AM
Ex-Valeant Official Says He Suspected Secret Financial StakeEx-Valeant Official Says He Suspected Secret Financial Stake
www.bloomberg.com - May 15 at 8:10 AM
VRX Investor Alert: Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) InvestorsVRX Investor Alert: Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors
finance.yahoo.com - May 15 at 8:10 AM
Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan ConferenceValeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference
finance.yahoo.com - May 15 at 8:10 AM
Zacks: Brokerages Anticipate Valeant Pharmaceuticals International Inc (VRX) Will Post Quarterly Sales of $2.05 BillionZacks: Brokerages Anticipate Valeant Pharmaceuticals International Inc (VRX) Will Post Quarterly Sales of $2.05 Billion
www.americanbankingnews.com - May 15 at 4:40 AM
Valeant Pharmaceuticals International (VRX) PT Set at $25.00 by Cantor FitzgeraldValeant Pharmaceuticals International (VRX) PT Set at $25.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 14 at 12:42 PM
 Analysts Anticipate Valeant Pharmaceuticals International Inc (VRX) Will Announce Earnings of $0.35 Per Share Analysts Anticipate Valeant Pharmaceuticals International Inc (VRX) Will Announce Earnings of $0.35 Per Share
www.americanbankingnews.com - May 13 at 3:19 AM
Valeant Pharmaceuticals International (VRX) Receives Market Perform Rating from BMO Capital MarketsValeant Pharmaceuticals International (VRX) Receives Market Perform Rating from BMO Capital Markets
www.americanbankingnews.com - May 11 at 5:43 PM
Valeant Pharmaceuticals International Inc (VRX) to Post Q1 2019 Earnings of $0.83 Per Share, Piper Jaffray ForecastsValeant Pharmaceuticals International Inc (VRX) to Post Q1 2019 Earnings of $0.83 Per Share, Piper Jaffray Forecasts
www.americanbankingnews.com - May 11 at 11:03 AM
FY2018 Earnings Forecast for Valeant Pharmaceuticals International Inc Issued By Jefferies Group (VRX)FY2018 Earnings Forecast for Valeant Pharmaceuticals International Inc Issued By Jefferies Group (VRX)
www.americanbankingnews.com - May 11 at 10:17 AM
Valeant To Seek Refinancing of its Existing Credit AgreementValeant To Seek Refinancing of its Existing Credit Agreement
finance.yahoo.com - May 10 at 8:07 AM
Valeant will borrow more than $3.82 blnValeant will borrow more than $3.82 bln
finance.yahoo.com - May 10 at 8:07 AM
Q3 2018 EPS Estimates for Valeant Pharmaceuticals International Inc (VRX) Cut by Jefferies GroupQ3 2018 EPS Estimates for Valeant Pharmaceuticals International Inc (VRX) Cut by Jefferies Group
www.americanbankingnews.com - May 10 at 7:38 AM
Valeant Pharmaceuticals International Inc (VRX) to Post Q2 2018 Earnings of $0.78 Per Share, Piper Jaffray ForecastsValeant Pharmaceuticals International Inc (VRX) to Post Q2 2018 Earnings of $0.78 Per Share, Piper Jaffray Forecasts
www.americanbankingnews.com - May 10 at 6:44 AM
TD Securities Increases Valeant Pharmaceuticals International (VRX) Price Target to $24.00TD Securities Increases Valeant Pharmaceuticals International (VRX) Price Target to $24.00
www.americanbankingnews.com - May 9 at 6:07 PM
Royal Bank of Canada Raises Valeant Pharmaceuticals International (VRX) Price Target to $19.00Royal Bank of Canada Raises Valeant Pharmaceuticals International (VRX) Price Target to $19.00
www.americanbankingnews.com - May 9 at 6:07 PM
Valeant Pharmaceuticals International (VRX) Given a $13.00 Price Target by JPMorgan Chase AnalystsValeant Pharmaceuticals International (VRX) Given a $13.00 Price Target by JPMorgan Chase Analysts
www.americanbankingnews.com - May 9 at 5:12 PM
Valeant Pharmaceuticals International (VRX) Earns "Hold" Rating from BTIG ResearchValeant Pharmaceuticals International (VRX) Earns "Hold" Rating from BTIG Research
www.americanbankingnews.com - May 9 at 3:17 PM
Valeant Pharmaceuticals International (VRX) Price Target Raised to $23.00 at Jefferies GroupValeant Pharmaceuticals International (VRX) Price Target Raised to $23.00 at Jefferies Group
www.americanbankingnews.com - May 9 at 3:17 PM
Valeant Pharmaceuticals International (VRX) Given a $13.00 Price Target by Piper Jaffray AnalystsValeant Pharmaceuticals International (VRX) Given a $13.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - May 9 at 12:09 PM
For the first time since 2015, were seeing organic growth: Valeant Pharma CEOFor the first time since 2015, we're seeing organic growth: Valeant Pharma CEO
finance.yahoo.com - May 9 at 8:05 AM
For the first time since 2015, we're seeing organic growt...For the first time since 2015, we're seeing organic growt...
finance.yahoo.com - May 9 at 8:05 AM
Valeant Pharma CEO: Seeing organic growth for first time ...Valeant Pharma CEO: Seeing organic growth for first time ...
finance.yahoo.com - May 9 at 8:05 AM
Cramer Remix: GE just got a huge break—the stock may have bottomedCramer Remix: GE just got a huge break—the stock may have bottomed
finance.yahoo.com - May 9 at 8:05 AM
Valeant will get a new name to shed its scandals, but will it work?Valeant will get a new name to shed its scandals, but will it work?
finance.yahoo.com - May 9 at 8:05 AM
Goldman Sachs Reiterates $16.00 Price Target for Valeant Pharmaceuticals International (VRX)Goldman Sachs Reiterates $16.00 Price Target for Valeant Pharmaceuticals International (VRX)
www.americanbankingnews.com - May 8 at 6:26 PM
Valeant Pharmaceuticals International (VRX) Given a $25.00 Price Target by Cantor Fitzgerald AnalystsValeant Pharmaceuticals International (VRX) Given a $25.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 8 at 3:28 PM
Valeant Pharmaceuticals International (VRX) Issues Quarterly  Earnings Results, Beats Estimates By $0.29 EPSValeant Pharmaceuticals International (VRX) Issues Quarterly Earnings Results, Beats Estimates By $0.29 EPS
www.americanbankingnews.com - May 8 at 9:36 AM
Earnings Reaction History: Valeant Pharmaceuticals International, 83.3% Follow-Through Indicator, 17.5% SensitiveEarnings Reaction History: Valeant Pharmaceuticals International, 83.3% Follow-Through Indicator, 17.5% Sensitive
www.nasdaq.com - May 8 at 8:04 AM
Valeant Pharmaceuticals to Change Its Name to Bausch HealthValeant Pharmaceuticals to Change Its Name to Bausch Health
www.wsj.com - May 8 at 8:04 AM
Valeant shares surge 5% on Q1 revenue beat, higher guidanceValeant shares surge 5% on Q1 revenue beat, higher guidance
finance.yahoo.com - May 8 at 8:04 AM
Valeant Pharma to rename itself as Bausch Health, lifts revenue outlookValeant Pharma to rename itself as Bausch Health, lifts revenue outlook
finance.yahoo.com - May 8 at 8:04 AM
Valeant: 1Q Earnings SnapshotValeant: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:04 AM
HC Wainwright Analysts Give Valeant Pharmaceuticals International (VRX) a $16.00 Price TargetHC Wainwright Analysts Give Valeant Pharmaceuticals International (VRX) a $16.00 Price Target
www.americanbankingnews.com - May 7 at 2:57 PM
Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose BrimonidineBausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine
finance.yahoo.com - May 7 at 8:08 AM
Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For ColonoscopiesSalix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies
finance.yahoo.com - May 7 at 8:08 AM
Nicox Provides First Quarter 2018 Business  and Financial ResultsNicox Provides First Quarter 2018 Business and Financial Results
feeds.benzinga.com - May 4 at 3:30 AM

SEC Filings

Valeant Pharmaceuticals Intl (NYSE:VRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Valeant Pharmaceuticals Intl (NYSE:VRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Valeant Pharmaceuticals Intl (NYSE VRX) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.